Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, Queensland, Australia.
PLoS Negl Trop Dis. 2012;6(11):e1896. doi: 10.1371/journal.pntd.0001896. Epub 2012 Nov 29.
Human African Trypanosomiasis (HAT) is caused by two trypanosome sub-species, Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Drugs available for the treatment of HAT have significant issues related to difficult administration regimes and limited efficacy across species and disease stages. Hence, there is considerable need to find new alternative and less toxic drugs. An approach to identify starting points for new drug candidates is high throughput screening (HTS) of large compound library collections. We describe the application of an Alamar Blue based, 384-well HTS assay to screen a library of 87,296 compounds against the related trypanosome subspecies, Trypanosoma brucei brucei bloodstream form lister 427. Primary hits identified against T.b. brucei were retested and the IC(50) value compounds were estimated for T.b. brucei and a mammalian cell line HEK293, to determine a selectivity index for each compound. The screening campaign identified 205 compounds with greater than 10 times selectivity against T.b. brucei. Cluster analysis of these compounds, taking into account chemical and structural properties required for drug-like compounds, afforded a panel of eight compounds for further biological analysis. These compounds had IC(50) values ranging from 0.22 µM to 4 µM with associated selectivity indices ranging from 19 to greater than 345. Further testing against T.b. rhodesiense led to the selection of 6 compounds from 5 new chemical classes with activity against the causative species of HAT, which can be considered potential candidates for HAT early drug discovery. Structure activity relationship (SAR) mining revealed components of those hit compound structures that may be important for biological activity. Four of these compounds have undergone further testing to 1) determine whether they are cidal or static in vitro at the minimum inhibitory concentration (MIC), and 2) estimate the time to kill.
人体感染非洲锥虫病(HAT)是由两种锥虫亚种引起的,即布氏锥虫罗得西亚亚种和布氏锥虫冈比亚亚种。现有的 HAT 治疗药物存在给药方案复杂和对不同种属及疾病阶段疗效有限等重大问题。因此,迫切需要寻找新的替代药物和毒性更小的药物。一种寻找新候选药物的方法是利用高通量筛选(HTS)对大型化合物库进行筛选。我们描述了一种基于阿尔玛蓝的 384 孔高通量筛选方法,用于筛选针对相关锥虫亚种布氏锥虫布鲁斯株血液期李斯特 427 的 87296 种化合物库。针对 T.b. brucei 鉴定的初筛阳性化合物被重新进行测试,并测定 T.b. brucei 和哺乳动物细胞系 HEK293 的 IC50 值,以确定每个化合物的选择性指数。筛选实验鉴定出 205 种对 T.b. brucei 具有大于 10 倍选择性的化合物。对这些化合物进行聚类分析,同时考虑到药物样化合物所需的化学和结构特性,确定了 8 种化合物用于进一步的生物学分析。这些化合物的 IC50 值范围为 0.22µM 至 4µM,相应的选择性指数范围为 19 至大于 345。进一步针对 T.b. rhodesiense 的测试导致从 5 个新的化学类别中选择了 6 种化合物,这些化合物对引起 HAT 的病原体具有活性,可被认为是 HAT 早期药物发现的潜在候选药物。构效关系(SAR)挖掘揭示了这些命中化合物结构中可能对生物活性重要的部分。其中 4 种化合物已经进行了进一步的测试,以 1)确定它们在最低抑菌浓度(MIC)下是杀菌还是抑菌,以及 2)估计杀菌时间。